샘플 요청 목록

 카트 문의
시장보고서
상품코드
1784094

세계의 RNA 요법 임상시험 시장

RNA Therapy Clinical Trials
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 244 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

RNA 요법 임상시험 세계 시장은 2030년까지 36억 달러에 달할 전망

2024년에 30억 달러로 추정되는 RNA 요법 임상시험 세계 시장은 2024-2030년 분석 기간 동안 CAGR 3.2%로 성장하여 2030년에는 36억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 RNA 간섭은 CAGR 2.6%를 기록하며 분석 기간 종료까지 17억 달러에 달할 것으로 예상됩니다. 안티센스 요법 분야의 성장률은 분석 기간 동안 CAGR 4.2%로 추정됩니다.

미국 시장은 7억 8,340만 달러로 추정, 중국은 CAGR 3.2%로 성장할 것으로 예측

미국의 RNA 요법 임상시험 시장은 2024년에 7억 8,340만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 3.2%로 2030년까지 5억 8,370만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.9%와 2.9%로 예측됩니다. 유럽에서는 독일이 CAGR 2.7%로 성장할 것으로 예측됩니다.

세계의 RNA 요법 임상시험 시장 - 주요 동향과 촉진요인 정리

RNA 기반 요법이 임상연구에서 주목받는 이유는 무엇일까?

RNA 기반 치료제는 여러 질환 영역에서 치료 패러다임을 바꿀 수 있는 잠재력을 가지고 있어 임상시험 분야에서 빠르게 주목받고 있습니다. 기존의 저분자 의약품과 달리 RNA 치료는 매우 특이적인 작용 기전을 가지고 있어 정확한 유전자 조절, 단백질 치환, 면역 조절을 가능하게 합니다. COVID-19 팬데믹 상황에서 mRNA 백신의 성공은 RNA 기반 플랫폼이 신속하고 확장 가능하며 매우 효과적인 치료제를 개발할 수 있는 엄청난 잠재력을 가지고 있다는 것을 입증했습니다. 백신 외에도 RNA 간섭(RNAi), 안티센스 올리고뉴클레오티드(ASO), 메신저 RNA(mRNA) 기반 약물이 희귀 유전성 질환부터 암, 신경 퇴행성 질환까지 다양한 질환에 대해 연구되고 있습니다. 또한, RNA 치료의 설계가 유연하기 때문에 신속한 변경과 개별화된 치료 접근이 가능하여 정밀의료 분야에서 특히 매력적입니다. 이러한 요인으로 인해 RNA 기반 의약품을 평가하는 임상시험이 급증하고 있으며, 제약회사와 연구기관은 RNA 치료제를 출시하기 위한 노력을 강화하고 있습니다.

RNA 전달 시스템의 발전이 임상시험의 성공률을 어떻게 높이고 있는가?

RNA 치료제 개발에서 가장 중요한 과제 중 하나는 효율적이고 표적화된 전달입니다. 최근 지질 나노입자(LNP), 고분자 기반 캐리어, 세포외 소포를 통한 전달의 발전은 RNA 약물의 안정성, 생체 이용률, 세포 내 흡수에 대한 기존의 장벽을 극복하고 있습니다. 특히 LNP 기술은 COVID-19 mRNA 백신의 성공에 중요한 역할을 했으며, 현재 종양학 및 희귀질환 치료 등 보다 광범위한 응용 분야에 최적화되고 있습니다. 또한, GalNAc(N-아세틸갈락토사민) 결합 siRNA와 같은 결합 전략은 간 표적 RNA 약물전달을 개선하고 잠재적인 치료 범위를 넓히고 있습니다. 이러한 기술 혁신은 임상시험 결과를 향상시키고, 독성을 줄이며, RNA 기반 치료에 대한 환자의 반응을 개선하고 있습니다. 전달 플랫폼의 지속적인 개선은 RNA 요법 임상시험의 중요한 실현 요소이며, 차세대 RNA 기반 치료제의 개발 일정을 앞당길 수 있습니다.

RNA 임상시험에 영향을 미치는 주요 규제 및 투자 동향은?

RNA 기반 치료제에 대한 규제 환경은 진화하고 있으며, FDA 및 EMA와 같은 기관은 유망한 RNA 의약품에 대한 신속한 승인 경로를 제공하고 있습니다. 특히 희귀질환 및 종양 분야에서는 RNA 기반 치료제에 획기적 치료제 및 희귀질환 치료제로 지정되는 경우가 증가하고 있습니다. 한편, 벤처 캐피털의 자금 유입과 민관 협력으로 임상시험이 확대되고 있으며, 주요 생명공학 기업들은 학술 연구 센터와 협력하여 RNA 의약품 개발을 서두르고 있습니다. 또한, 바이오마커 기반 임상시험 설계의 발전으로 보다 효율적인 환자 계층화가 가능해져 임상시험의 성공률이 높아지고 있습니다. 규제 당국이 RNA 치료의 증가 추세에 적응함에 따라 업계는 여러 적응증에 대한 새로운 임상시험의 시작이 급증하여 시장 성장을 더욱 촉진하고 있습니다.

RNA 요법 임상시험 시장의 급성장 원동력은?

RNA 요법 임상시험 시장의 성장은 RNA 기반 백신의 성공, RNA 의약품 개발에 대한 투자 증가, RNA 전달 기술의 발전 등 여러 요인에 의해 주도되고 있습니다. 유전성 질환, 신경퇴행성 질환, 암의 유병률 증가는 혁신적인 RNA 기반 중재에 대한 수요를 가속화하고 있습니다. AI를 활용한 임상시험 플랫폼의 확대는 RNA 합성 및 변형 기술의 향상과 함께 의약품 개발 프로세스를 더욱 간소화하고 있습니다. 맞춤형 의료의 추진도 RNA 치료에 대한 관심을 높이고 있으며, 모듈식 설계로 맞춤형 치료 접근법에 빠르게 적응할 수 있습니다. 또한, 유리한 규제 정책과 의료진 및 환자들 사이에서 RNA 기반 치료법에 대한 수용도가 높아짐에 따라 탄탄한 임상시험 생태계가 구축되고 있습니다. RNA 의약품의 치료 가능성이 검증되고 있는 현재, 강력한 과학적 혁신, 규제 당국의 지원, 업계 협력 강화에 힘입어 시장은 지속적으로 확대될 것으로 보입니다.

부문

모달리티(RNA 간섭, 안티센스 요법, 메신저 RNA, 기타), 임상시험 단계(단계 i, 단계 II, 단계 III, 단계 IV), 치료 분야(희귀질환, 항감염증, 항암, 신경, 소화기/대사, 근골격계, 심혈관계 호흡기, 감각 기관, 기타)

조사 대상 기업 사례

  • Abivax
  • Alnylam Pharmaceuticals
  • Arcturus Therapeutics
  • Aro Biotherapeutics
  • Arrowhead Pharmaceuticals
  • AstraZeneca
  • Avidity Biosciences
  • Biogen Inc.
  • BioNTech SE
  • Capricor Therapeutics
  • Cartesian Therapeutics
  • CureVac AG
  • Dicerna Pharmaceuticals
  • eTheRNA immunotherapies
  • Ethris GmbH
  • GSK(GlaxoSmithKline)
  • Ionis Pharmaceuticals
  • Lexeo Therapeutics
  • Moderna Inc.
  • Nutcracker Therapeutics

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가가 선별한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

ksm

Global RNA Therapy Clinical Trials Market to Reach US$3.6 Billion by 2030

The global market for RNA Therapy Clinical Trials estimated at US$3.0 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. RNA interference, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Antisense therapy segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$783.4 Million While China is Forecast to Grow at 3.2% CAGR

The RNA Therapy Clinical Trials market in the U.S. is estimated at US$783.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$583.7 Million by the year 2030 trailing a CAGR of 3.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global RNA Therapy Clinical Trials Market - Key Trends & Drivers Summarized

Why Are RNA-Based Therapies Gaining Traction In Clinical Research?

RNA-based therapies are rapidly gaining prominence in the clinical trial landscape, driven by their potential to revolutionize treatment paradigms across multiple disease areas. Unlike traditional small-molecule drugs, RNA therapies offer highly specific mechanisms of action, enabling precise gene regulation, protein replacement, and immune modulation. The success of mRNA vaccines during the COVID-19 pandemic has demonstrated the immense potential of RNA-based platforms in developing rapid, scalable, and highly effective therapeutics. Beyond vaccines, RNA interference (RNAi), antisense oligonucleotides (ASOs), and messenger RNA (mRNA)-based drugs are being explored for conditions ranging from rare genetic disorders to cancer and neurodegenerative diseases. Additionally, the flexibility of RNA therapy design allows for rapid modifications and personalized treatment approaches, making them particularly attractive in precision medicine. These factors have propelled a surge in clinical trials evaluating RNA-based drugs, with pharmaceutical companies and research institutions intensifying their efforts to bring RNA therapeutics to market.

How Are Advances In RNA Delivery Systems Enhancing Clinical Trial Success?

One of the most significant challenges in RNA therapy development has been efficient and targeted delivery. Recent advancements in lipid nanoparticles (LNPs), polymer-based carriers, and extracellular vesicle-mediated delivery are overcoming previous barriers to RNA drug stability, bioavailability, and cellular uptake. LNP technology, in particular, played a critical role in the success of COVID-19 mRNA vaccines and is now being optimized for broader applications, including oncology and rare disease therapies. Additionally, conjugation strategies, such as GalNAc (N-acetylgalactosamine)-conjugated siRNAs, are improving liver-targeted RNA drug delivery, expanding their potential therapeutic scope. These innovations are enhancing clinical trial outcomes, reducing toxicity, and improving patient responses to RNA-based treatments. The continuous refinement of delivery platforms is a key enabler of RNA therapy clinical trials, accelerating the development timeline for next-generation RNA-based therapeutics.

What Are The Key Regulatory & Investment Trends Influencing RNA Clinical Trials?

The regulatory landscape for RNA-based therapeutics is evolving, with agencies such as the FDA and EMA providing accelerated approval pathways for promising RNA drugs. Breakthrough therapy designations and orphan drug status are increasingly being granted to RNA-based treatments, particularly in the fields of rare diseases and oncology. Meanwhile, the influx of venture capital funding and public-private partnerships is driving clinical trial expansion, with major biotech firms collaborating with academic research centers to fast-track RNA drug development. Additionally, advancements in biomarker-driven clinical trial designs are enabling more efficient patient stratification, enhancing trial success rates. As regulatory agencies adapt to the growing wave of RNA therapies, the industry is witnessing a surge in new trial initiations across multiple indications, further fueling market growth.

What Is Driving The Rapid Growth Of The RNA Therapy Clinical Trials Market?

The growth in the RNA therapy clinical trials market is driven by several factors, including the success of RNA-based vaccines, increasing investment in RNA drug development, and advancements in RNA delivery technologies. The rising prevalence of genetic disorders, neurodegenerative diseases, and cancer is accelerating the demand for innovative RNA-based interventions. The expansion of AI-powered clinical trial platforms, coupled with improvements in RNA synthesis and modification techniques, is further streamlining the drug development process. The push toward personalized medicine is also driving interest in RNA therapies, as their modular design enables rapid adaptation for individualized treatment approaches. Additionally, favorable regulatory policies and the growing acceptance of RNA-based therapies among healthcare providers and patients are creating a robust clinical trial ecosystem. As research continues to validate the therapeutic potential of RNA drugs, the market is set for continued expansion, backed by strong scientific innovation, regulatory support, and increasing industry collaboration.

SCOPE OF STUDY:

The report analyzes the RNA Therapy Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Modality (RNA interference, Antisense therapy, Messenger RNA, Others); Clinical Trials Phase (Phase I, Phase II, Phase III, Phase IV); Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 37 Featured) -

  • Abivax
  • Alnylam Pharmaceuticals
  • Arcturus Therapeutics
  • Aro Biotherapeutics
  • Arrowhead Pharmaceuticals
  • AstraZeneca
  • Avidity Biosciences
  • Biogen Inc.
  • BioNTech SE
  • Capricor Therapeutics
  • Cartesian Therapeutics
  • CureVac AG
  • Dicerna Pharmaceuticals
  • eTheRNA immunotherapies
  • Ethris GmbH
  • GSK (GlaxoSmithKline)
  • Ionis Pharmaceuticals
  • Lexeo Therapeutics
  • Moderna Inc.
  • Nutcracker Therapeutics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • RNA Therapy Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Neurological Diseases Spurs Demand for RNA Therapy Clinical Trials in Central Nervous System Disorders
    • Increasing Role of Personalized Medicine in RNA Therapeutics Expands Addressable Market for RNA-Based Clinical Trials
    • Regulatory Advancements in RNA Therapy Approvals Strengthen the Pathway for Clinical Trials and Accelerate Product Development
    • Growth in RNA Vaccine Research and Applications Drives Demand for RNA Therapy Clinical Trials Post-COVID-19
    • Surge in Academic and Industry Collaboration Drives RNA Therapy Innovation and Clinical Trial Advancements
    • Enhanced Focus on Rare and Undruggable Diseases Creates Opportunities for RNA Therapeutics in Clinical Trials
    • Technological Advancements in mRNA Delivery Systems Propel Growth in RNA Therapy Clinical Trials
    • Integration of AI and Machine Learning in RNA Drug Discovery Expands Clinical Trial Opportunities and Accelerates Development
    • Increasing Consumer and Patient Advocacy for Advanced Therapeutics Drives Interest in RNA Therapy Clinical Trials
    • Expanding Global Healthcare Infrastructure and Clinical Trial Networks Create New Growth Opportunities for RNA Therapy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World RNA Therapy Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for RNA Therapy Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for RNA Therapy Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for RNA interference by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for RNA interference by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for RNA interference by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antisense therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antisense therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Antisense therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Messenger RNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Messenger RNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Messenger RNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Modalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Anti-infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Anti-infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Anti-infective by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Anticancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Anticancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Anticancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Neurological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Neurological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Neurological by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Alimentary / Metabolic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Alimentary / Metabolic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Alimentary / Metabolic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Musculoskeletal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Musculoskeletal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Musculoskeletal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Cardiovascular Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Cardiovascular Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Cardiovascular Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Sensory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Sensory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Sensory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Rare Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • JAPAN
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • CHINA
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • EUROPE
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for RNA Therapy Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for RNA Therapy Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • FRANCE
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • GERMANY
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: UK 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: UK 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • RNA Therapy Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 158: Rest of World Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of World Historic Review for RNA Therapy Clinical Trials by Modality - RNA interference, Antisense therapy, Messenger RNA and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of World 15-Year Perspective for RNA Therapy Clinical Trials by Modality - Percentage Breakdown of Value Sales for RNA interference, Antisense therapy, Messenger RNA and Other Modalities for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of World Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of World Historic Review for RNA Therapy Clinical Trials by Therapeutic Areas - Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of World 15-Year Perspective for RNA Therapy Clinical Trials by Therapeutic Areas - Percentage Breakdown of Value Sales for Anti-infective, Anticancer, Neurological, Alimentary / Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas and Rare Diseases for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of World Recent Past, Current & Future Analysis for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of World Historic Review for RNA Therapy Clinical Trials by Clinical Trials Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of World 15-Year Perspective for RNA Therapy Clinical Trials by Clinical Trials Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제